doi: 10.1161/hc0102.101362
(Circulation. 2002;105:15.)
© 2002 American Heart Association, Inc.
Clinical Investigation and Reports |
Impact of Infectious Burden on Extent and Long-Term Prognosis of Atherosclerosis
From the Department of Medicine II (C.E.-K., H.J.R., S.B., C.B., H.K., J.M.), the Department of Medical Statistics and Documentation (G.R., A.V.), and the Department of Clinical Chemistry (G.H.), Johannes Gutenberg University Mainz, Germany; and EUROIMMUN (W.S.), Lübeck, Germany.
Correspondence to Christine Espinola-Klein, MD, University Clinic Mainz, Department of Medicine II, Langenbeckstrasse 1, 55101 Mainz, Germany. E-mail espinola{at}mail.uni-mainz.de
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Recent findings suggest a causative role of infections in the pathogenesis of atherosclerosis. In hypothesizing an association between infectious agents and the development of atherosclerosis, we would expect a correlation to the extent of atherosclerosis. Moreover, this effect could be multiplied by the number of pathogens to which an individual had been exposed.
Methods and Results— In 572 patients, IgG or IgA antibodies to herpes simplex virus 1 and 2, cytomegalovirus, Epstein-Barr virus, Hemophilus influenzae, Chlamydia pneumoniae, Mycoplasma pneumoniae, and Helicobacter pylori were measured. The extent of atherosclerosis was determined by coronary angiography, carotid duplex sonography, and evaluation of the ankle-arm index. Elevated IgA antibodies against C pneumoniae (P<0.04) and IgG antibodies against H pylori (P<0.02), cytomegalovirus (P<0.05), and herpes simplex virus 2 (P<0.01) were associated with advanced atherosclerosis (
2 vascular regions), adjusted for age, sex, cardiovascular risk factors, and highly sensitive C-reactive protein. Infectious burden divided into 0 to 3, 4 to 5, and 6 to 8 seropositivities was significantly associated with advanced atherosclerosis, with an odds ratio (95% CI) of 1.8 (1.2 to 2.6) for 4 to 5 (P<0.01) and 2.5 (1.2 to 5.1) for 6 to 8 seropositivities (P<0.02) (adjusted). After a mean follow-up of 3.2 years, cardiovascular mortality rate was 7.0% in patients with advanced atherosclerosis and seropositive for 0 to 3 pathogens compared with 20.0% in those seropositive for 6 to 8 pathogens.
Conclusions— Our results support the hypothesis that infectious agents are involved in the development of atherosclerosis. We showed a significant association between infectious burden and the extent of atherosclerosis. Moreover, the risk for future death was increased by the number of infectious pathogens, especially in patients with advanced atherosclerosis.
Key Words: infection • atherosclerosis • carotid arteries • coronary disease • peripheral vascular disease
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Inflammation in the arterial vessel wall is considered to play an important role in the pathogenesis of atherosclerosis. Pathological studies have demonstrated the presence of inflammatory cells such as macrophages and T lymphocytes in every stage of the atherosclerotic process.1 Recent prospective studies have shown that several markers of systemic inflammation, such as C-reactive protein or fibrinogen, are associated with stable and unstable angina pectoris, peripheral arterial disease, and carotid artery stenosis.2,3
See p 2
An association of viral infection with atherosclerosis was first reported in the 1970s, when experimental infection of germ-free chickens with an avian herpesvirus was found to produce arterial disease.4 Currently there is also evidence that other Herpesviridae such as cytomegalovirus (CMV) and herpes simplex virus (HSV) may contribute to the pathogenesis of atherosclerosis.5,6 Associations of human atherosclerosis with bacteria such as Chlamydia pneumoniae and Helicobacter pylori also have been reported.7,8 It has been hypothesized that the number of different pathogens to which an individual has been exposed might promote a synergistic inflammatory response that could exacerbate atherosclerosis.9–11
Most investigators have focused on the association of different pathogens with advanced atherosclerosis in one vascular bed, such as coronary artery disease, carotid artery stenosis, or early carotid atherosclerosis. There is little information available about the influence of any bacterial or viral infection on the extent of atherosclerosis including more than one vascular area in the arterial vessel tree.12–15
It is known that patients with atherosclerosis in multiple vascular regions have a higher cardiovascular mortality rate than patients with limited disease,16 but until now there are no data available as to whether this risk could be influenced by an infection to various infectious pathogens. We therefore undertook the present study in 572 patients undergoing coronary angiography and additionally performed carotid duplex sonography and Doppler sonography in the peripheral arteries to address the following questions:
(1) Is there a correlation between the extent of atherosclerosis and persistent infections with different bacterial or viral pathogens?
(2) Is there a relation between the extent of atherosclerosis and the number of infectious pathogens to which an individual has been exposed?
(3) Does a previous infection with multiple pathogens have any influence on adverse outcome in patients with extended atherosclerosis in various vascular regions?
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Study Population
Between November 1996 and July 1998, a total of 1168 consecutive patients had been admitted to the 2nd Medical Department of the University Clinic Mainz, Germany, for diagnostic heart catheterization. Five hundred seventy-two patients had been randomly chosen as the subgroup, and additional examinations of the carotid and leg arteries were performed. The coronary syndrome was stable in 320 (56%) patients and unstable in 103 patients (18%); 68 patients (12%) had acute myocardial infarction and 81 patients (14%) had come to the hospital for treatment of other diseases (eg, hypertensive heart disease). Cardiovascular risk factors such as family history of cardiovascular disease, smoking, diabetes mellitus, hypertension, and hyperlipidemia were defined according to a previous publication.11
A total of 570 of 572 patients (99.6%) were followed up during a mean of 3.2 years (minimum, 1.9; maximum, 4.1 years). Patients either presented at our clinic (87.2%) or were interviewed by telephone by trained medical staff. Follow-up information was obtained about death from cardiovascular causes (n=40, 7.0%) or death of causes not related to heart disease (n=15, 2.6%). Information about the cause of death was obtained from hospital or general practitioner charts.
In general, study participants had German nationality and, particularly, were inhabitants of the Rhein-Main Area. The study was approved by the ethics committee of the University of Mainz. Participation was voluntary, and each study subject gave written informed consent.
Evaluation of Vascular Status
Coronary angiography was performed in all study patients. Patients were considered to have coronary artery disease (CAD) after coronary artery bypass surgery or in the presence of at least one stenosis with diameter >30% according to coronary angiography by visual assessment in a major coronary artery after sublingual administration of 0.8 mg nitroglycerin.
Patients were defined as having carotid artery disease if they had previously undergone carotid surgery or if a significant stenosis could be detected by duplex sonography (7.5-MHz transducer, Advanced Technology Laboratories, Ultramark 9). The percent diameter stenosis was estimated for each internal and external carotid artery by means of both color duplex imaging and Doppler peak systolic flow velocities. In accordance with previous reports, peak velocities of >1.4 m/s were assumed to indicate a >50% diameter lumen stenosis.17
Peripheral vascular status was investigated by Doppler flow velocity study with the use of a 4-MHz transducer for the femoral and popliteal arteries and an 8-MHz transducer for the foot arteries. Clinically manifest peripheral artery disease was diagnosed after a previous peripheral revascularization or if an ankle-arm index (systolic blood pressure ankle/arm) of <0.9 could be detected in at least one pedal artery with pathological monophasic Doppler waves.18
Patients were classified into three groups according to the extent of atherosclerosis: In 61 patients, examinations of coronary, carotid, and leg arteries were normal (control, 11%). In 265 patients, at least one coronary artery stenosis was detected; however, carotid duplex sonography and Doppler examination of the leg arteries was normal (limited disease, 46%). Patients with CAD and additional carotid and/or leg artery stenosis were defined as having advanced atherosclerosis (n=246, 43%).
Laboratory Methods
Blood samples were drawn from each subject after an overnight fasting period. Serum was centrifuged at 4000g for 10 minutes, immediately divided into aliquots, and frozen at -80°C until analysis. Each study subject’s serum was tested for specific IgG class antibodies against CMV, Epstein-Barr virus (EBV), HSV-1, HSV-2, C pneumoniae, Mycoplasma pneumoniae, Haemophilus influenzae, and H pylori as well as IgA class antibodies against C pneumoniae, M pneumoniae, H pylori, and EBV through the use of quantitative in vitro ELISAs or indirect immunofluorescence (C pneumoniae and H influenzae) (EUROIMMUN). In the IgG ELISA a value of >20 relative units per mL and in the IgA ELISA a ratio of >1 was considered positive according to the manufacturer’s instructions. Concerning indirect immunofluorescence, the starting dilution was 1:100 and specific fluorescence patterns at or above these dilutions were considered positive. The anti-chlamydia antibody test is based on broad-reactive chlamydial inclusions. C-reactive protein (CRP) was determined by a highly sensitive, latex particle–enhanced immunoassay (detection range, 0 to 20 mg/dL, Roche Diagnostics).
Statistical Analysis
Differences between groups were tested by 
2 test for categorical variables and by Kruskal-Wallis test for continuous variables. Logistic regression analysis was performed, including the number of seropositivities in categories (0 to 3, 4 to 5, and 6 to 8) or titers of each pathogen as continuous variables for the end point advanced atherosclerosis. Confidence intervals at the 95% level were calculated for the odds ratios. Odds ratios were described for the increase of 1 SD for pathogens evaluated by ELISA and for seropositivity for pathogens evaluated by indirect immunofluorescence assay. Survival was assessed by Cox regression analysis and risk was described by hazard ratios (HRs) and the corresponding 95% CI. Logistic regression analysis and Cox regression analysis were performed adjusted for age, sex, cardiovascular risk factors (smoking, hyperlipidemia, arterial hypertension, diabetes mellitus, and family history of cardiovascular disease), and CRP in a multivariate model. A value of P
0.05 was considered locally significant. Computations were carried out with SPSS version 10.0.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Associations Between Each Pathogen and the Extent of Atherosclerosis
Baseline characteristics according to the extent of atherosclerosis are shown in Table 1. Table 2 demonstrates the correlation of baseline pathogen IgG and IgA antibodies with advanced atherosclerosis in the study population. After adjustment for age, sex, risk factors, and CRP, only IgA seropositivity to C pneumoniae (P<0.04) and elevated IgG antibodies to H pylori (P<0.02), CMV, and HSV-2 (P<0.01) revealed an independent association with advanced atherosclerosis.
|
|
Infectious Burden and Extent of Atherosclerosis
For analysis of the association between atherosclerosis and the aggregate number of antipathogen antibodies, we used IgG seropositivities to HSV-1 and HSV-2, CMV, and H influenzae as well as IgA seropositivities to H pylori, M pneumoniae, C pneumoniae, and EBV. Because of the limited number of subjects with very low and very high pathogen burden, we stratified patients into groups with 0 to 3, 4 to 5, and 6 to 8 seropositivities. Patients were divided into those with high (>0.5 mg/dL, n=273, 48%) or low (0.5 mg/dL, n=299, 52%) CRP level.
An increasing pathogen burden was significantly associated with the extent of atherosclerosis (Figure 1) in patients with high and low CRP levels. We found an association between the extent of atherosclerosis and increasing numbers of infectious pathogens to which an individual has been exposed, with an OR (95% CI) of 1.8 (1.2 to 2.6) for patients seropositive for 4 to 5 pathogens (P=0.002) and 2.5 (1.2 to 5.1) for patients seropositive for 6 to 8 pathogens (P<0.02) compared with patients seropositive for 0 to 3 pathogens (adjusted) (Table 3).
|
|
All results concerning association between infectious burden and extent of atherosclerosis point in the same direction, and the results were consistent in all analyses.
Further analyses were performed separating seropositivities into bacterial infections and Herpetoviridae. Because of the limited number of patients with low and high pathogen burden, we combined patients with 0 to 1 and with 3 to 4 seropositivities. Bacterial burden divided into 0 to 1 and 2 and 3 to 4 pathogens was independently associated with advanced atherosclerosis, especially in patients with high CRP levels (Figure 2). We found an OR of 1.6 (1.1 to 2.4) for 2 (P=0.02) and 2.1 (1.3 to 3.4) for 3 to 4 pathogens (P=0.002) compared with those seropositive for up to 1 bacterial pathogen (adjusted) (Table 3). In contrast, analyses performed for viral burden did not reveal an association with the extent of atherosclerosis (Figure 3 and Table 3).
|
|
Infectious Burden and Cardiovascular Death
Cardiovascular death was associated with the extent of atherosclerosis (Figure 4). There were no deaths in the control group, compared with a mortality rate of 3.5% in patients with limited and 13.9% in patients with advanced disease (P<0.0001). The HR (95% CI) for cardiovascular death was 3.0 (1.4 to 6.3) for patients with advanced disease compared with those with limited disease (adjusted) (P<0.005, Table 4).
|
|
We also found a correlation between cardiovascular death and the number of seropositivities. Mortality rate was 3.1% in patients seropositive for up to 3 pathogens, 9.8% in patients seropositive for 4 to 5 pathogens, and 15.0% for those seropositive for 6 to 8 pathogens (P<0.001). The HR for future cardiovascular death was 2.5 (1.2 to 5.4) in patients seropositive for 4 to 5 pathogens (P<0.02) and 2.9 (1.2 to 9.6) for patients seropositive for 6 to 8 pathogens (P<0.02) compared with those seropositive for up to 3 pathogens (adjusted).
Further analyses were performed to evaluate mortality rates for each group of atherosclerosis according to the number of seropositivities. In the group of patients with limited disease, cardiovascular mortality rate was 1.4% in patients seropositive for 0 to 3 pathogens compared with 7.7% in patients seropositive for 6 to 8 pathogens. For patients with advanced disease, mortality rate was 7.0% in patients seropositive for 0 to 3 pathogens compared with 20.0% in those seropositive for 6 to 8 pathogens. We found an HR (95% CI) of 10.8 (2.0 to 58.5) for patients with advanced atherosclerosis and highest infectious burden (6 to 8 pathogens) compared with those with limited disease and lowest infectious burden (0 to 3 pathogens, adjusted, P=0.005).
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Inflammatory mechanisms have been implicated in the pathogenesis of atherosclerosis, and previous investigators have reported an association between elevated inflammatory markers and the development of atherosclerosis.2,3 Many studies have shown associations between atherosclerosis and different pathogens, and early investigations showed the presence of infectious pathogens in the whole arterial vessel tree.1,5–8
In the present study, we selected eight pathogens because of two main characteristics: They are obligate intracellular pathogens except for H influenzae and M pneumoniae, and they all develop persistent antibodies targeted to the pathogen. Furthermore, six pathogens produce a life-long latent (Herpetoviridae) or persistent infection, whereas H influenzae and M pneumoniae are not known to provoke a persistent infection although they establish life-long persistence of antibodies. In all pathogens we determined anti-IgG antibodies; in some pathogens IgA antibodies also were measured because of the nearly 100% prevalence of IgG (EBV) and because of reports suggesting that IgA antibodies might reflect more recent and/or repeated infectious episodes (C pneumoniae, H pylori, M pneumoniae).7
Although there is controversy regarding the role of each infectious pathogen in different vascular regions, according to the literature we found associations between elevated antibodies against 5 of the 8 evaluated pathogens and the extent of atherosclerosis. The antibody titers for C pneumoniae, H pylori, H influenzae, CMV, and HSV-2 were related to the extent of atherosclerosis. After adjustment for age, sex, classic cardiovascular risk factors, and CRP, the relation persisted for all except H influenzae.
According to the hypothesis from Zhu et al9 and Epstein et al,10 it seems unlikely that one specific pathogen causes atherosclerosis. This is supported by our findings that show a significant relation between the number of infectious pathogens to which an individual has been exposed and the extent of atherosclerosis. It is known that some pathogens, such as C pneumoniae, can induce macrophage foam cell formation and that this effect might be increased if an individual has been infected by multiple pathogens.1,19 It has been hypothesized previously that the infectious pathogen contains proteins homologous to parts of the host proteins, resulting in an immune response called infection-induced molecular mimicry.20 It is possible that such an effect could be multiplied if multiple pathogens are involved in the atherosclerotic process.9–11
The association between pathogen burden and extent of atherosclerosis was mainly driven by seropositivities to bacterial infections, and we could not find an influence of seropositivities to Herpesviridae. However, in a previous publication, we showed a higher influence of Herpesviridae on adverse outcome compared with bacterial pathogens in patients with CAD.11 Over that, we found a stronger association between bacterial burden and extent of disease in patients with high CRP level, possibly indicating higher inflammation processes at the arterial wall. It might be possible that bacterial pathogens are involved in the development and long-term progression of atherosclerosis, but Herpesviridae are responsible for plaque instability, acceleration of atherosclerosis, and development of cardiovascular events.
Zhu et al9 and Epstein et al10 reported a positive association between infectious burden and the prevalence of CAD and cardiovascular events. Results from Rupprecht et al11 support this hypothesis, showing an increased cardiovascular mortality rate in patients with documented CAD and high infectious burden. Our results showed an increased cardiovascular mortality rate according to the extent of atherosclerosis, and our results implicate an additional increase of mortality rate according to the number of infections to which a patient has been exposed.
Our data consistently suggest that an increasing number of seropositivities to infectious pathogens is associated with the extent of atherosclerosis and with cardiovascular death. However, several prospective studies revealed disparate results that may derive from several causes. In contrast to our study, each of these studies was restricted to a homogeneous population without proven CAD21,22 or even more, to a highly selected population.23,24 Although such highly selected populations offer several advantages (eg, elimination of various confounders), these populations may not represent other populations (eg, those with high incidence of risk factors). Furthermore, most of these studies determined only IgG antibodies and did not take into account possible interactions with markers of inflammation or immune response.
Limitations
Several limitations of our study should be considered. Antibodies are weak predictors in prospective studies on advanced atherosclerosis and cardiovascular events, but in cross-sectional studies, elevated antibody titers can reflect the activation of a chronic infection or a reinfection. Because this is a cross-sectional study, we cannot be sure that infection precedes the development of atherosclerosis. Although this is a cross-sectional study concerning the association between the extent of atherosclerosis and infectious burden, we included a prospective approach with regard to clinical events. The epidemiology of atherosclerosis is different in coronary, carotid, and leg arteries; furthermore, the abdominal aorta, which is also an important vascular area, has not been evaluated. We evaluated a patient cohort with a high prevalence of CAD and a mean age of 63 years because we included only patients scheduled for coronary angiography, which is the gold standard for evaluating CAD.
Conclusions
We demonstrated that increasing numbers of infectious pathogens were significantly related to the extent of atherosclerosis and to adverse long-term outcome. Our results are compatible with the concept that infections are involved in the development of atherosclerosis and that infections with multiple pathogens may augment the risk conveyed by one pathogen.
Received August 6, 2001; revision received October 16, 2001; accepted October 19, 2001.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Epstein SE, Zhou YF, Zhu J. Infection and atherosclerosis: emerging mechanistic paradigms. Circulation. 1999; 100: 20–28.
2.
Jander S, Sitzer M, Schumann R, et al. Inflammation in high-grade carotid stenosis: a possible role for macrophages and T cells in plaques destabilization. Stroke. 1998; 29: 1625–1630.
3.
Anderson JL, Carlquist JF, Muhlestein JB, et al. Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J Am Coll Cardiol. 1998; 32: 35–41.
4.
Fabricant CG, Fabricant J, Litrenta MM, et al. Virus-induced atherosclerosis. J Exp Med. 1978; 148: 335–340.
5. Yamashiroya HM, Ghosh L, Yang R, et al. Herpesviridae in the coronary arteries and aorta of young trauma victims. Am J Pathol. 1988; 130: 71–79.[Abstract]
6.
Blankenberg S, Rupprecht H-J, Poiret O, et al. Cytomegalovirus infection with interleukin-6 response predicts cardiovascular mortality in patients with coronary artery disease. Circulation. 2001; 103: 2915–2921.
7.
Mendall MA, Goggin PM, Molineaux N, et al. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J. 1994; 71: 437–439.
8. Saikku P, Leinonen M, Tenkanen L, et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med. 1992; 116: 273–278.
9. Zhu J, Quyyumi AA, Norman JE, et al. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am J Cardiol. 2000; 85: 140–146.[CrossRef][Medline] [Order article via Infotrieve]
10.
Epstein SE, Zhu J, Burnett MS, et al. Infection and atherosclerosis: potential roles of pathogen burden and molecular mimicry. Arterioscler Thromb Vasc Biol. 2000; 20: 1417–1420.
11.
Rupprecht HJ, Blankerberg S, Bickel C, et al. Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation. 2001; 104: 25–31.
12. Korner I, Blatz R, Wittig I, et al. Serological evidence of Chlamydia pneumoniae lipopolysaccharide antibodies in atherosclerosis of various vascular regions. Vasa. 1999; 28: 259–263.[CrossRef][Medline] [Order article via Infotrieve]
13.
Chiu B, Viira E, Tucker W, et al. Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in the atherosclerosis of the carotid artery. Circulation. 1997; 96: 2144–2148.
14.
Danesh J, Wong Y, Ward M, et al. Chronic infection with Helicobacter pylori, Chlamydia pneumoniae, or cytomegalovirus: population based study of coronary heart disease. Heart. 1999; 81: 245–247.
15.
Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Are morphological or functional changes in the carotid artery wall associated with Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, or herpes simplex virus infection? Stroke. 2000; 31: 2127–2133.
16. Cupples LA, Gagnon DR, Wong ND, et al. Preexisting cardiovascular conditions and long-term prognosis after initial myocardial infarction: the Framingham Study. Am Heart J. 1993; 125: 863–872.[CrossRef][Medline] [Order article via Infotrieve]
17. Arbeille P, Desombre C, Aesh B, et al. Quantification and assessment of carotid artery lesions: degree of stenosis and plaque volume. J Clin Ultrasound. 1995; 23: 113–124.[Medline] [Order article via Infotrieve]
18.
Newman AB, Shemanski L, Manolio TA, et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1999; 19: 538–545.
19. Kalayoglu MV, Byrne GI. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis. 1998; 177: 725–729.[Medline] [Order article via Infotrieve]
20. Wick G, Perschinka H, Xu Q. Autoimmunity and atherosclerosis. Am Heart J. 1999; 138: S444–S449.[CrossRef][Medline] [Order article via Infotrieve]
21.
Danesh J, Whincup P, Walker M, et al. Chlamydia pneumoniae IgG titers and coronary artery disease: prospective study and meta-analysis. BMJ. 2000; 321: 208–213.
22.
Whincup P, Danesh J, Walker M, et al. Prospective study of potentially virulent strains of Helicobacter pylori and coronary heart disease in middle-aged men. Circulation. 2000; 101: 1647–1652.
23.
Ridker PM, Hennekens CH, Stampfer MJ, et al. Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke. Circulation. 1998; 98: 2796–2799.
24.
Ridker PM, Hennekens CH, Buring JE, et al. Baseline IgG antibody titres to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women. Ann Intern Med. 1999; 131: 573–577.
This article has been cited by other articles:
 |
|
 |
|
  M. S. V. Elkind, P. Ramakrishnan, Y. P. Moon, B. Boden-Albala, K. M. Liu, S. L. Spitalnik, T. Rundek, R. L. Sacco, and M. C. Paik Infectious Burden and Risk of Stroke: The Northern Manhattan Study Arch Neurol, November 9, 2009; (2009) 2009.271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Epstein, J. Zhu, A. H. Najafi, and M. S. Burnett Insights Into the Role of Infection in Atherogenesis and in Plaque Rupture Circulation, June 23, 2009; 119(24): 3133 - 3141. [Full Text] [PDF]
|
|
|
|
 |
|
 R. B. Gombos, V. Wolan, K. McDonald, and D. G. Hemmings Impaired vascular function in mice with an active cytomegalovirus infection Am J Physiol Heart Circ Physiol, April 1, 2009; 296(4): H937 - H945. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zajacova, J. B. Dowd, and A. E. Aiello Socioeconomic and Race/Ethnic Patterns in Persistent Infection Burden Among U.S. Adults J Gerontol A Biol Sci Med Sci, February 4, 2009; (2009) gln012v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Pesonen, E. Andsberg, A. Grubb, H. Rautelin, S. Meri, K. Persson, M. Puolakkainen, S. Sarna, and H. Ohlin Elevated infection parameters and infection symptoms predict an acute coronary event Therapeutic Advances in Cardiovascular Disease, December 1, 2008; 2(6): 419 - 424. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. Naiki, R. Sorrentino, M. H. Wong, K. S. Michelsen, K. Shimada, S. Chen, A. Yilmaz, A. Slepenkin, N. W. J. Schroder, T. R. Crother, et al. TLR/MyD88 and Liver X Receptor {alpha} Signaling Pathways Reciprocally Control Chlamydia pneumoniae-Induced Acceleration of Atherosclerosis J. Immunol., November 15, 2008; 181(10): 7176 - 7185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. P. Tobin, G. T. Henehan, R. P. Murphy, J. C. Atherton, A. F. Guinan, S. W. Kerrigan, D. Cox, P. A. Cahill, and P. M. Cummins Helicobacter pylori-induced inhibition of vascular endothelial cell functions: a role for VacA-dependent nitric oxide reduction Am J Physiol Heart Circ Physiol, October 1, 2008; 295(4): H1403 - H1413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Espinola-Klein, H. J. Rupprecht, C. Bickel, K. Lackner, S. Savvidis, C. M. Messow, T. Munzel, S. Blankenberg, and for the AtheroGene Investigators Different Calculations of Ankle-Brachial Index and Their Impact on Cardiovascular Risk Prediction Circulation, August 26, 2008; 118(9): 961 - 967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Steptoe, A Shamaei-Tousi, A Gylfe, B Henderson, S Bergstrom, and M Marmot Socioeconomic status, pathogen burden and cardiovascular disease risk Heart, December 1, 2007; 93(12): 1567 - 1570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Krebs, E. Scandella, B. Bolinger, D. Engeler, S. Miller, and B. Ludewig Chronic Immune Reactivity Against Persisting Microbial Antigen in the Vasculature Exacerbates Atherosclerotic Lesion Formation Arterioscler Thromb Vasc Biol, October 1, 2007; 27(10): 2206 - 2213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.-F. Dai, J.-W. Lin, J.-H. Kao, C.-N. Hsu, F.-T. Chiang, J.-L. Lin, Y.-H. Chou, K.-L. Hsu, C.-D. Tseng, Y.-Z. Tseng, et al. The Effects of Metabolic Syndrome Versus Infectious Burden on Inflammation, Severity of Coronary Atherosclerosis, and Major Adverse Cardiovascular Events J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2532 - 2537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. F. Novak, W. J. Diamond, S. Kirakodu, R. Peyyala, K. W. Anderson, R. C. Montelaro, and T. A. Mietzner Efficacy of the De Novo-Derived Antimicrobial Peptide WLBU2 against Oral Bacteria Antimicrob. Agents Chemother., May 1, 2007; 51(5): 1837 - 1839. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kishimoto A Novel Approach to the Suppression of Atherosclerosis by Fc{gamma} Receptor Blockade Circ. Res., November 24, 2006; 99(11): 1154 - 1155. [Full Text] [PDF]
|
|
|
|
|
|
X. Yang, V. Murthy, K. Schultz, J. B. Tatro, K. A. Fitzgerald, and D. Beasley Toll-like receptor 3 signaling evokes a proinflammatory and proliferative phenotype in human vascular smooth muscle cells Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2334 - H2343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Mohammad, M. Morran, B. Slotterbeck, D. W. Leaman, Y. Sun, H. v. Grafenstein, S.-C. Hong, and M. F. McInerney Dysregulated Toll-like receptor expression and signaling in bone marrow-derived macrophages at the onset of diabetes in the non-obese diabetic mouse Int. Immunol., July 1, 2006; 18(7): 1101 - 1113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Circulation, June 20, 2006; 113(24): e873 - e923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Stroke, June 1, 2006; 37(6): 1583 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Fernandez-Real, A. Lopez-Bermejo, J. Vendrell, M.-J. Ferri, M. Recasens, and W. Ricart Burden of Infection and Insulin Resistance in Healthy Middle-Aged Men Diabetes Care, May 1, 2006; 29(5): 1058 - 1064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhang, A. Niessner, T. Nakajima, W. Ma-Krupa, S. L. Kopecky, R. L. Frye, J. J. Goronzy, and C. M. Weyand Interleukin 12 Induces T-Cell Recruitment Into the Atherosclerotic Plaque Circ. Res., March 3, 2006; 98(4): 524 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. H. Shen, L. Zhang, B. Utama, J. Wang, Y. Gan, X. Wang, J. Wang, L. Chen, G. M. Vercellotti, J. S. Coselli, et al. Human cytomegalovirus inhibits Akt-mediated eNOS activation through upregulating PTEN (phosphatase and tensin homolog deleted on chromosome 10) Cardiovasc Res, February 1, 2006; 69(2): 502 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Crimmins and C. E. Finch Infection, inflammation, height, and longevity PNAS, January 10, 2006; 103(2): 498 - 503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Yang, D. Coriolan, K. Schultz, D. T. Golenbock, and D. Beasley Toll-Like Receptor 2 Mediates Persistent Chemokine Release by Chlamydia pneumoniae-Infected Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, November 1, 2005; 25(11): 2308 - 2314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Espinola-Klein, S. Blankenberg, and T. Munzel Editorial Comment--Is Heme Oxygenase-1 a Causal Player for Plaque Stability? Stroke, September 1, 2005; 36(9): 1901 - 1903. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Andraws, J. S. Berger, and D. L. Brown Effects of Antibiotic Therapy on Outcomes of Patients With Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials JAMA, June 1, 2005; 293(21): 2641 - 2647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ngeh and C. Goodbourn Chlamydia pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila in Elderly Patients With Stroke (C-PEPS, M-PEPS, L-PEPS): A Case-Control Study on the Infectious Burden of Atypical Respiratory Pathogens in Elderly Patients With Acute Cerebrovascular Disease Stroke, February 1, 2005; 36(2): 259 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. de Kruif, E. C.M. van Gorp, T. T. Keller, J. M. Ossewaarde, and H. ten Cate Chlamydia pneumoniae infections in mouse models: relevance for atherosclerosis research Cardiovasc Res, February 1, 2005; 65(2): 317 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Sheehan, P M Kearney, S O Sullivan, C Mongan, E Kelly, and I J Perry Acute coronary syndrome and chronic infection in the Cork coronary care case-control study Heart, January 1, 2005; 91(1): 19 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Davi, M. Neri, A. Falco, D. Festi, T. Taraborelli, G. Ciabattoni, S. Basili, F. Cuccurullo, and C. Patrono Helicobacter Pylori Infection Causes Persistent Platelet Activation In Vivo Through Enhanced Lipid Peroxidation Arterioscler Thromb Vasc Biol, January 1, 2005; 25(1): 246 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Michelsen, T. M. Doherty, P. K. Shah, and M. Arditi TLR Signaling: An Emerging Bridge from Innate Immunity to Atherogenesis J. Immunol., November 15, 2004; 173(10): 5901 - 5907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. M. Miller, G. Rodgers, J. A. Charlesworth, B. Kirkland, S. R. Severson, T. E. Rasmussen, M. Yagubyan, J. C. Rodgers, F. R. Cockerill III, R. L. Folk, et al. Evidence of nanobacterial-like structures in calcified human arteries and cardiac valves Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1115 - H1124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Fliser, K. Buchholz, H. Haller, and for the EUropean Trial on Olmesartan and Pravastat Antiinflammatory Effects of Angiotensin II Subtype 1 Receptor Blockade in Hypertensive Patients With Microinflammation Circulation, August 31, 2004; 110(9): 1103 - 1107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Ludewig, P. Krebs, and E. Scandella Immunopathogenesis of atherosclerosis J. Leukoc. Biol., August 1, 2004; 76(2): 300 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Marson, R. M. Lawn, and T. Mikita Oxidized Low Density Lipoprotein Blocks Lipopolysaccharide-induced Interferon {beta} Synthesis in Human Macrophages by Interfering with IRF3 Activation J. Biol. Chem., July 2, 2004; 279(27): 28781 - 28788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W. Ketterer, G. Mahr, J. J. Cao, M. Hudson, S. Smith, and W. Knysz What's "Unstable" in Unstable Angina? Psychosomatics, June 1, 2004; 45(3): 185 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.H. Shen, B. Utama, J. Wang, M. Raveendran, D. Senthil, W.J. Waldman, J.D. Belcher, G. Vercellotti, D. Martin, B.M. Mitchelle, et al. Human Cytomegalovirus Causes Endothelial Injury Through the Ataxia Telangiectasia Mutant and p53 DNA Damage Signaling Pathways Circ. Res., May 28, 2004; 94(10): 1310 - 1317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sander, K. Winbeck, J. Klingelhofer, T. Etgen, and B. Conrad Progression of Early Carotid Atherosclerosis Is Only Temporarily Reduced After Antibiotic Treatment of Chlamydia pneumoniae Seropositivity Circulation, March 2, 2004; 109(8): 1010 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Potena, G. Frascaroli, F. Grigioni, T. Lazzarotto, G. Magnani, L. Tomasi, F. Coccolo, L. Gabrielli, C. Magelli, M. P. Landini, et al. Hydroxymethyl-Glutaryl Coenzyme A Reductase Inhibition Limits Cytomegalovirus Infection in Human Endothelial Cells Circulation, February 3, 2004; 109(4): 532 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Mattila Does periodontitis cause heart disease? Eur. Heart J., December 1, 2003; 24(23): 2079 - 2080. [Full Text] [PDF]
|
|
|
|
|
|
H C Routledge, J G Ayres, and J N Townend Why cardiologists should be interested in air pollution Heart, December 1, 2003; 89(12): 1383 - 1388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M Cummings, D. E King, and A. G Mainous III C-Reactive Protein, Antiinflammatory Drugs, and Quality of Life in Diabetes Ann. Pharmacother., November 1, 2003; 37(11): 1593 - 1597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Burgner diagnosis is based on clinical features BMJ, October 18, 2003; 327(7420): 917 - 917. [Full Text] [PDF]
|
|
|
|
|
|
P. J. Lindsberg and A. J. Grau Inflammation and Infections as Risk Factors for Ischemic Stroke Stroke, October 1, 2003; 34(10): 2518 - 2532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. O'Connor, M. W. Dunne, M. A. Pfeffer, J. B. Muhlestein, L. Yao, S. Gupta, R. J. Benner, M. R. Fisher, and T. D. Cook Azithromycin for the Secondary Prevention of Coronary Heart Disease Events: The WIZARD Study: A Randomized Controlled Trial JAMA, September 17, 2003; 290(11): 1459 - 1466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Grahame-Clarke, N. N. Chan, D. Andrew, G. L. Ridgway, D. J. Betteridge, V. Emery, H. M. Colhoun, and P. Vallance Human Cytomegalovirus Seropositivity Is Associated With Impaired Vascular Function Circulation, August 12, 2003; 108(6): 678 - 683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Yuan, C. Kishimoto, H. Sano, K. Shioji, Y. Xu, and M. Yokode Immunoglobulin treatment suppresses atherosclerosis in apolipoprotein E-deficient mice via the Fc portion Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H899 - H906. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Fernandez-Real and W. Ricart Insulin Resistance and Chronic Cardiovascular Inflammatory Syndrome Endocr. Rev., June 1, 2003; 24(3): 278 - 301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Benagiano, A. Azzurri, A. Ciervo, A. Amedei, C. Tamburini, M. Ferrari, J. L. Telford, C. T. Baldari, S. Romagnani, A. Cassone, et al. T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions PNAS, May 27, 2003; 100(11): 6658 - 6663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Rupp and M. Maass Egr-1, a Major Link Between Infection and Atherosclerosis? Circ. Res., May 16, 2003; 92 (9): e78 - e78. [Full Text] [PDF]
|
|
|
|
|
|
M. Prager, Z. Turel, W. S. Speidl, G. Zorn, C. Kaun, A. Niessner, G. Heinze, I. Huk, G. Maurer, K. Huber, et al. Chlamydia pneumoniae in Carotid Artery Atherosclerosis: A Comparison of Its Presence in Atherosclerotic Plaque, Healthy Vessels, and Circulating Leukocytes From the Same Individuals Stroke, December 1, 2002; 33(12): 2756 - 2761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-J. Neumann Chlamydia pneumoniae-Atherosclerosis Link: A Sound Concept in Search for Clinical Relevance Circulation, November 5, 2002; 106(19): 2414 - 2416. [Full Text] [PDF]
|
|
|
|
|
|
D. Sander, K. Winbeck, J. Klingelhofer, T. Etgen, and B. Conrad Reduced Progression of Early Carotid Atherosclerosis After Antibiotic Treatment and Chlamydia pneumoniae Seropositivity Circulation, November 5, 2002; 106(19): 2428 - 2433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Espinola-Klein, H.-J. Rupprecht, S. Blankenberg, C. Bickel, H. Kopp, A. Victor, G. Hafner, W. Prellwitz, W. Schlumberger, and J. Meyer Impact of Infectious Burden on Progression of Carotid Atherosclerosis Stroke, November 1, 2002; 33(11): 2581 - 2586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. F.M. Stone, M. A. Mendall, J.-C. Kaski, T. M. Edger, P. Risley, J. Poloniecki, A. J. Camm, and T. C. Northfield Effect of Treatment for Chlamydia pneumoniae and Helicobacter pylori on Markers of Inflammation and Cardiac Events in Patients With Acute Coronary Syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA) Circulation, September 3, 2002; 106(10): 1219 - 1223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gabrielli, L. Santarelli, A. Gasbarrini, C. Espinola-Klein, H. J. Rupprecht, S. Blankenberg, C. Bickel, H. Kopp, J. Meyer, G. Rippin, et al. Role for Chronic Infections in Atherosclerosis? * Response Circulation, August 13, 2002; 106 (7): e32 - e32. [Full Text] [PDF]
|
|
|
|
|
|
J. Auer, R. Berent, T. Weber, and B. Eber Influenza Virus Infection, Infectious Burden, and Atherosclerosis Stroke, June 1, 2002; 33(6): 1454 - 1455. [Full Text] [PDF]
|
|
|
|
|
|
P. M. Ridker On Evolutionary Biology, Inflammation, Infection, and the Causes of Atherosclerosis Circulation, January 1, 2002; 105(1): 2 - 4. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||